In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox)

Journal of Applied Toxicology

Volumn 23, Issue 6, 2003, Pages 447-451

  Petroianu, Georg ^a   Arafat, Kholoud ^a   Kosanovic, Melita ^a   Saleh, Ayman ^a   Camasamudram, Vijayasarathy ^a   Hasan, Mohamed Y ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cholinesterase; Metoclopramide; Organophosphate; Pralidoxime

Indexed keywords

ACETYLCHOLINESTERASE; BENZAMIDE DERIVATIVE; CHOLINESTERASE INHIBITOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROCYTE ENZYME; METOCLOPRAMIDE; MIPAFOX; ORGANOPHOSPHATE PESTICIDE; OXIME DERIVATIVE; PARAOXON; PRALIDOXIME; SEROTONIN 4 AGONIST;

ADULT; ARTICLE; BLOOD TOXICITY; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPOSURE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NEUROPATHY; NEUROTOXICITY; NORMAL HUMAN; PHOTOMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VOLUNTEER;

ACETYLCHOLINESTERASE; ADULT; CHOLINESTERASE INHIBITORS; ERYTHROCYTES; FEMALE; HUMANS; ISOFLUROPHATE; MALE; METOCLOPRAMIDE; MIDDLE AGED; PARAOXON; RECEPTORS, DOPAMINE D2;

EID: 0344465448     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.936     Document Type: Article

References (28)

1. Bergner AD, O'Neill JJ. 1958. A modification of the Koelle technique for use with oximes. J. Histochem. Cytochem. 6: 72-74.
2. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R. 1996. Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol. Res. 34: 65-72.
3. Dart RC, Goldfrank LR, Chyka PA, Lotzer D, Woolf AD, McNally J, Snodgrass WR, Olson KR, Scharman E, Geller RJ, Spyker D, Kraft M, Lipsy R. 2000. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann. Emerg. Med. 36: 126-132.
4. Geldmacher-von Mallinkrodt M, Urbach HJ, Kittel H, Lindorf HH. 1969. Zur Messung der in vivo and in vitro Reaktivierbarkeit alkylphosphatvergifteter Serumcholinesterase durch 2-PAM und Toxogonin mit verschiedenen Substanzen. Z Klin. Chem. Klin. Bioochem. 7: 480-485.
5. Graham SG, Crossley AWA. 1995. The characteristics of the Inhibition of serum cholinesterase by metoclopramide. Eur. J. Clin. Pharmacol. 48: 225-228.
6. Heitmann R, Felgenhauer K. 1969. On the esterolytic effect of toxogonin. Dtsch. Med. Wochenschr. 94: 1583,
7. Jeyaratnam J. 1990. Acute pesticide poisoning: a major global health problem. World Health Stat. Q. 43: 139-144.
8. Johnson MK, Jacobsen D, Meredith TJ, Eyer P, Heath AJ, Ligtenstein DA, Marrs TC, et al. 2000. Evaluation of antidotes for poisoning by organophosphourus pesticides. Emerg. Med. 12: 22-37.
9. Karalliedde L. 1999. Organophosphorus poisoning and anaesthesia. Anaesthesia 54: 1073-1088.
10. Levine R. 1991. Recognized and possible effects of pesticides in humans. In Handbook of Pesticide Toxiclogy, General Principles, Vol. 1, Hayes WJ, Laws ER (eds). Academic Press: San Diego, 275-360.
11. Martindale. 1999. The Complete Drug Reference (32nd edn), Parfitt K. (ed.). Pharmaceutical Press: Taunton, MA; 992-993.
12. McGovern EM, Grevel J, Bryson SM. 1986. Pharmacokinetics of high-dose metoclopramide in cancer patients. Clin Pharmacokin 11: 415-424.
13. Missler A, Petroianu G, Zuleger K, Ruefer R. 2001. Pralidoxime induces significant esteratic pseudo-activity in vivo (mini-pigs). J. Clin. Pharmacol. 41: 1017 (Abstract 14).
14. Namba T. 1971. Cholinesterase inhibition by organophosphourus compounds, and its clinical effects. Bull. WHO 44: 289-307.
15. Namba T, Nolte CT, Jackrel J, Grob D. 1971. Poisoning due to organophosphate insecticides: acute and chronic manifestations. Am. J. Med. 50: 457-492.
16. Nenner M, Erdmann WD. 1969. Toxogonin - a catalyst of ester hydrolysis? Ger. Med. Mon. 14: 194-196.
17. Pannbacker RG, Oehme FW. 2003. Pralidoxime hydrolysis of thiocholine esters. Vet. Hum. Toxicol. 45: 39-40.
18. Peter JV, Cherian AM. 2000. Organic insecticides. Anaesth. Intens. Care 28: 11-21.
19. Petroianu G, Toomes LM, Petroianu A, Bergeler W, Rüfer R. 1998. Control of blood pressure, heart rate and haematocrit during high-dose intravenous paraoxon exposure in mini pigs. J. Appl. Toxicol. 18: 293-298.
20. Petroianu G, Hardt F, Toomes LM, Petroianu A, Bergeler W, Rüfer R. 2001a. High-dose i.v. paraoxon exposure does not cause organophosphate-induced delayed neuropathy (OPIDN) in mini pigs. J. Appl. Toxicol. 21: 263-268.
21. Petroianu G, Roth C, Beha U, Fischer J, Bergler W, Rüfer R. 2001b. Pralidoxime and I-lactate effects in vitro on the inhibition of acetylcholinesterase by paraoxon: pralidoxime does not confer superior protection. J. Appl. Toxicol. 21: 7-13.
22. Petroianu G, Kuehn F, Thyes C, Ewald V, Missler A. 2003. In vitro protection of plasma cholinesterases by metoclopramide from inhibition by paraoxon. J. Appl. Toxicol. 23: 75-79.
23. Ross-Lee LM, Eadie MJ, Hooper WD, Bochner F. 1981. Single-dose pharmacokinetics of metoclopramicle. Eur. J. Clin. Pharmacol. 20: 465-471.
24. Sidell FR, Groff WA, Kaminskis A. 1972. Pralidoxime methanesulfonate, plasma levels and pharmacokinetics after oral administration to man. J. Pharm. Sci. 61: 1136-1140.
25. Swartz RD, Sidell FR. 1973. Effects of heart and exercise on the elimination of pralidoxime in man. Clin. Pharmacol. Ther. 14: 83-89.
26. Van Helden HP, Busker RW, Melchers BPC, Bruijnzeel PLB. 1996. Pharmacological effects of oximes: how relevant are they? Arch. Toxicol. 70: 779-786.
27. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. 1999. Improved determination of acetylcholinesterase activity in human whole blood. Clin. Chim. Acta. 288: 73-90.
28. Zoch E. 1971. Die Wirkung organischer Phosphorsäureester bzw. Phosphorsäureester auf versch. Enzyme. Arzneim. Forsch. 21: 181-187.